Aldevron has expanded its leadership team by appointing Mike Busch as Vice President of Human Resources.
Don Kania, Ph.D., has been appointed to the Board of Directors of Aldevron. Dr. Kania joins Michael Chambers, CEO of Aldevron; and Ethan K. Liebermann and Mark H. Carter, both from TA Associates, on the board.
Aldevron and Integrated DNA Technologies, Inc. (IDT), a supplier of custom nucleic acid and genome editing products, have announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFiTM Cas9 Nuclease—which is patented by IDT. The product will be manufactured for research, clinical, and commercial use.
Aldevron, a global provider of plasmid DNA and gene editing enzymes used to support novel cancer therapies, will be a Platinum sponsor of the 2017 Believe Ball organized by the Emily Whitehead Foundation. In its inaugural year, the Believe Ball will bring together T-Cell therapy patients and their families with the doctors, scientists, researchers, and others who helped develop this therapy.
Henry Hebel has been named Chief Operating Officer of Aldevron, a leading global provider of contract plasmid DNA manufacturing, protein production and antibody discovery services.
Aldevron licenses minicircle technology to support collaboration with Myeloma Crowd and the development of multiple myeloma treatments
Aldevron to produce minicircles to support cell therapy applications
Aldevron, along with the Myeloma Crowd, a non-profit foundation dedicated to multiple myeloma patient education, advocacy and research funding, will collaborate to support research toward the advancement of treatments and a cure for multiple myeloma.
Aldevron, a leading biotechnology contract manufacturing and development organization, is now using a 30-liter single-use fermentation system for manufacturing nucleic acids and proteins.
(Fargo, N.D. and Boston, Mass.), January 24, 2017 – Aldevron, a contract development and manufacturing organization specializing in the production of plasmid DNA, proteins and antibodies, today announced it has received a growth investment from TA Associates, a leading global growth private equity firm. Aldevron’s management retains a significant portion of ownership in the company and will continue to run the company. Financial terms of the transaction were not disclosed.
Founded in 1998, Aldevron manufactures biologics for research, clinical and diagnostic applications. The company’s products are used to manufacture novel treatments for a wide range of indications, including cancer, infectious disease, pediatric disorders and rare diseases. Aldevron’s custom products are used extensively in the fields of gene therapy and gene editing. The company is headquartered in Fargo, North Dakota, and has additional facilities in Madison, Wisconsin, and Freiburg, Germany.